
Ascendis Pharma’s Bold Vision: Transforming Growth with Innovative Therapies
Ascendis Pharma AS targets 2025 with growth-focused strategies after recent successes. Skytrofa has achieved a 6.5% market share in the US endocrinology sector. Transcon PTH is now a leading FDA-approved treatment for adult hypoparathyroidism. The company enjoys a strong financial position with